Article

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

2022-07-06

Abstract excerpt

<title>Abstract</title> <p>Hypomethylating agents (HMA) remain the backbone of therapy for treating higher risk myelodysplastic syndromes (HR-MDS), however less than 20% of these patients achieve a complete remission (CR). Preliminary data have reported promising higher response rate combining HMA with Venetoclax as first line therapy (1L) as well as activity in HMA failure MDS. We identified 1193 higher risk MDS...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f6be8920-606a-5d20-a5d4-7e2c94ccb125
DOI: 10.21203/rs.3.rs-1785642/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeDOI 10.21203/rs.3.rs-1785642/v1Read

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeSemantic proximity Read

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patientsSemantic proximity Read

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched studySemantic proximity Read

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.Semantic proximity Read

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort studySemantic proximity Read

[Novel therapies for MDS and future prospects].Semantic proximity Read

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read

TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.Semantic proximity Read

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read